Literature DB >> 33778746

Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.

Michelle D Sakala1, Nicole E Curci1, William R Masch1, Mishal Mendiratta-Lala1, Erica B Stein1, Ashish P Wasnik1, Andrew P Sciallis1, Shitanshu Uppal1, Mark D Pearlman1, Katherine E Maturen1.   

Abstract

Purpose: To examine radiologic-histopathologic correlation and the diagnostic performance of transvaginal US prior to risk-reducing salpingo-oophorectomy (RRSO) in women at high risk for tubo-ovarian carcinoma (TOC). Materials and
Methods: This retrospective study included 147 women (mean age, 49 years; age range, 28-75 years) at high risk for TOC who underwent transvaginal US within 6 months of planned RRSO between May 1, 2007, and March 14, 2018. Histopathologic results were reviewed. Fellowship-trained abdominal radiologists reinterpreted transvaginal US findings by using standardized descriptors. Descriptive statistical analysis and multiple logistic regression were performed.
Results: Of the 147 women, 136 had mutations in BRCA1, BRCA2, Lynch syndrome, BRIP1, and RAD51D genes, and 11 had a family history of TOC. Histopathologic reports showed 130 (88.4%) benign nonneoplastic results, 10 (6.8%) benign neoplasms, five (3.4%) malignant neoplasms, and two (1.4%) isolated p53 signature lesions. Transvaginal US results showed benign findings in 95 (64.6%) women and abnormal findings in 11 (7.5%) women; one or both ovaries were not visualized in 41 (27.9%) women. Hydrosalpinx was absent in all TOC and p53 signature lesions at transvaginal US. Transvaginal US had 20% sensitivity (one of five), 93% specificity (132 of 142), 9% positive predictive value (one of 11), and 97% negative predictive value (132 of 136) for TOC. Cancer was detected in one of five women at transvaginal US, and three of five false-negative lesions were microscopic or very small.
Conclusion: Preoperative transvaginal US had low sensitivity for detecting TOC in women at high risk for TOC. Clinically relevant precursors and early cancers were too small to be detected.Keywords: Genital/Reproductive, UltrasoundSupplemental material is available for this article.© RSNA, 2020. 2020 by the Radiological Society of North America, Inc.

Entities:  

Year:  2020        PMID: 33778746      PMCID: PMC7983748          DOI: 10.1148/rycan.2020190086

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  37 in total

Review 1.  Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement.

Authors:  Deborah Levine; Douglas L Brown; Rochelle F Andreotti; Beryl Benacerraf; Carol B Benson; Wendy R Brewster; Beverly Coleman; Paul Depriest; Peter M Doubilet; Steven R Goldstein; Ulrike M Hamper; Jonathan L Hecht; Mindy Horrow; Hye-Chun Hur; Mary Marnach; Maitray D Patel; Lawrence D Platt; Elizabeth Puscheck; Rebecca Smith-Bindman
Journal:  Radiology       Date:  2010-05-26       Impact factor: 11.105

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

4.  Can Coregistered Photoacoustic Tomography and US Be Used in Screening for Ovarian Cancer?

Authors:  Deborah Levine
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

5.  Ovarian-Adnexal Reporting Lexicon for Ultrasound: A White Paper of the ACR Ovarian-Adnexal Reporting and Data System Committee.

Authors:  Rochelle F Andreotti; Dirk Timmerman; Beryl R Benacerraf; Genevieve L Bennett; Tom Bourne; Douglas L Brown; Beverly G Coleman; Mary C Frates; Wouter Froyman; Steven R Goldstein; Ulrike M Hamper; Mindy M Horrow; Marta Hernanz-Schulman; Caroline Reinhold; Lori M Strachowski; Phyllis Glanc
Journal:  J Am Coll Radiol       Date:  2018-08-24       Impact factor: 5.532

6.  Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Authors:  C Bethan Powell; Lee-may Chen; Jane McLennan; Beth Crawford; Charles Zaloudek; Joseph T Rabban; Dan H Moore; John Ziegler
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

7.  Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.

Authors:  R Manchanda; A Abdelraheim; M Johnson; A N Rosenthal; E Benjamin; C Brunell; M Burnell; L Side; S Gessler; E Saridogan; D Oram; I Jacobs; U Menon
Journal:  BJOG       Date:  2011-03-10       Impact factor: 6.531

8.  ACR Appropriateness Criteria® Ovarian Cancer Screening.

Authors:  Pari V Pandharipande; Kathryn P Lowry; Caroline Reinhold; Mostafa Atri; Carol B Benson; Priyadarshani R Bhosale; Edward D Green; Stella K Kang; Yulia Lakhman; Katherine E Maturen; Refky Nicola; Gloria M Salazar; Thomas D Shipp; Lynn Simpson; Betsy L Sussman; Jennifer Uyeda; Darci J Wall; Bradford Whitcomb; Carolyn M Zelop; Phyllis Glanc
Journal:  J Am Coll Radiol       Date:  2017-11       Impact factor: 5.532

9.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

10.  Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.

Authors:  Adam N Rosenthal; Lindsay S M Fraser; Susan Philpott; Ranjit Manchanda; Matthew Burnell; Philip Badman; Richard Hadwin; Ivana Rizzuto; Elizabeth Benjamin; Naveena Singh; D Gareth Evans; Diana M Eccles; Andy Ryan; Robert Liston; Anne Dawnay; Jeremy Ford; Richard Gunu; James Mackay; Steven J Skates; Usha Menon; Ian J Jacobs
Journal:  J Clin Oncol       Date:  2017-02-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.